CCA
ALXN

Column Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Column Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-29
Closed -$3K – 818
2019
Q4 		$3K Buy
+29
New +$3.1K ﹤0.01% 597

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Column Capital Advisors's ALXN Position: Q1 2020 in Review

Column Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 29 shares — an estimated $3K sold.

Column Capital Advisors first reported a position in ALXN in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Column Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Column Capital Advisors sold 29 Alexion Pharmaceuticals shares in Q1 2020, an estimated $3K.
  • Column Capital Advisors first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Column Capital Advisors's Alexion Pharmaceuticals position peaked at $3K in Q4 2019.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.